» Articles » PMID: 23390181

Alzheimer Disease in the United States (2010-2050) Estimated Using the 2010 Census

Overview
Journal Neurology
Specialty Neurology
Date 2013 Feb 8
PMID 23390181
Citations 1182
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To provide updated estimates of Alzheimer disease (AD) dementia prevalence in the United States from 2010 through 2050.

Methods: Probabilities of AD dementia incidence were calculated from a longitudinal, population-based study including substantial numbers of both black and white participants. Incidence probabilities for single year of age, race, and level of education were calculated using weighted logistic regression and AD dementia diagnosis from 2,577 detailed clinical evaluations of 1,913 people obtained from stratified random samples of previously disease-free individuals in a population of 10,800. These were combined with US mortality, education, and new US Census Bureau estimates of current and future population to estimate current and future numbers of people with AD dementia in the United States.

Results: We estimated that in 2010, there were 4.7 million individuals aged 65 years or older with AD dementia (95% confidence interval [CI] = 4.0-5.5). Of these, 0.7 million (95% CI = 0.4-0.9) were between 65 and 74 years, 2.3 million were between 75 and 84 years (95% CI = 1.7-2.9), and 1.8 million were 85 years or older (95% CI = 1.4-2.2). The total number of people with AD dementia in 2050 is projected to be 13.8 million, with 7.0 million aged 85 years or older.

Conclusion: The number of people in the United States with AD dementia will increase dramatically in the next 40 years unless preventive measures are developed.

Citing Articles

Exploring the Efficacy and Safety of Nutritional Supplements in Alzheimer's Disease.

Gualtieri P, Frank G, Cianci R, Ciancarella L, Romano L, Ortoman M Nutrients. 2025; 17(5).

PMID: 40077790 PMC: 11901643. DOI: 10.3390/nu17050922.


Progress in AAV-Mediated In Vivo Gene Therapy and Its Applications in Central Nervous System Diseases.

Wang S, Xiao L Int J Mol Sci. 2025; 26(5).

PMID: 40076831 PMC: 11899905. DOI: 10.3390/ijms26052213.


Machine learning uncovers novel sex-specific dementia biomarkers linked to autism and eye diseases.

Khan A, Ghasemi A, Ingram K, Ay A J Alzheimers Dis Rep. 2025; 9:25424823251317177.

PMID: 40034518 PMC: 11864256. DOI: 10.1177/25424823251317177.


Real-World Insights Into Dementia Diagnosis Trajectory and Clinical Practice Patterns Unveiled by Natural Language Processing: Development and Usability Study.

Paek H, Fortinsky R, Lee K, Huang L, Maghaydah Y, Kuchel G JMIR Aging. 2025; 8:e65221.

PMID: 39999185 PMC: 11878476. DOI: 10.2196/65221.


Target the Heart: a new axis of Alzheimer's disease prevention.

Heller L, Lowe A, Del Rosario Hernandez T, Gore S, Chatterjee M, Creton R bioRxiv. 2025; .

PMID: 39975163 PMC: 11838187. DOI: 10.1101/2025.01.27.634057.


References
1.
Kokmen E, Chandra V, Schoenberg B . Trends in incidence of dementing illness in Rochester, Minnesota, in three quinquennial periods, 1960-1974. Neurology. 1988; 38(6):975-80. DOI: 10.1212/wnl.38.6.975. View

2.
Kawas C, Gray S, Brookmeyer R, Fozard J, Zonderman A . Age-specific incidence rates of Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology. 2000; 54(11):2072-7. DOI: 10.1212/wnl.54.11.2072. View

3.
Hebert L, Scherr P, Bienias J, Bennett D, Evans D . Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 2003; 60(8):1119-22. DOI: 10.1001/archneur.60.8.1119. View

4.
Hebert L, Scherr P, Beckett L, Albert M, Pilgrim D, Chown M . Age-specific incidence of Alzheimer's disease in a community population. JAMA. 1995; 273(17):1354-9. View

5.
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan E . Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984; 34(7):939-44. DOI: 10.1212/wnl.34.7.939. View